In this 7th DDup issue, we delve into the unique new kidney platforms poised to change the trajectory of kidney disease research and therapeutics development. Evotec has embarked on a novel collaboration model with Kidney Research UK, University of Bristol, University of Cambridge, University of Nottingham and the Mario Negri Institute in Bergamo...

Collaboration is focused on first-in-class therapies to treat dermatological diseases Collaboration leverages a novel approach to disrupt cell signalling, validated by EVT Innovate

Dual-listing of Evotec AG share in TecDAX and MDAX as of 24 September 2018 

The collaboration will focus on targeted protein degradation Evotec's panomics and data analytics platforms will be leveraged Financials include upfront payment as well as significant potential milestone-based payments and royalties

First-in-Human Trials Planned for the Fourth Quarter of 2019 IND-Enabling Studies to Be Completed Utilizing Evotec INDiGO Platform